Selective induction of apoptosis in hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate cysteine protease P32

Journal of Clinical Investigation

Volumn 98, Issue 11, 1996, Pages 2588-2596

  Adjei, Philip N ^a   Kaufmann, Scott H ^a   Leung, Wai Yee ^b   Mao, Fei ^b   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

^b MOLECULAR PROBES INC   (United States)

Author keywords

camptothecin; CPP32; etoposide; interleukin 1 converting enzyme; poly(ADP ribose) polymerase

Indexed keywords

CAMPTOTHECIN; CYSTEINE PROTEINASE; GYRASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

EID: 0029807603     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119078     Document Type: Article

References (70)

1. Wingo, P.A., T. Tong, and S. Bolden. 1995. Cancer statistics. C.A. Cancer J. Clin. 45:8-30.
2. Ringe, B., R. Pichlmayr, C. Wittekind, and G. Tusch. 1991. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J. Surg. 15:270-285.
3. Bruix, J., A. Castells, X. Montanya, X. Calvet, C. Bru, C. Ayuso, L. Jover, L. Garcia, R. Vilana, L. Boix, and J. Rodes. 1994. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology. 20:643-650.
4. Colombo, M. 1993. Hepatocellular carcinoma in cirrhotics. Semin. Liver Dis. 13:374-383.
5. Pelletier, G., A. Roche, O. Ink, M.L. Anciaux, S. Derhy, P. Rougier, C. Lenoir, P. Attali, and J.P. Etienne. 1990. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J. Hepatol. 11:181-184.
6. Trinchet, J.C., A.A. Rached, M. Beaugrand, D. Mathieu, S. Chevret, and C. Chastang. 1995. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 332: 1256-1261.
7. Dive, C., C.A. Evans, and A.D. Whetton. 1992. Induction of apoptosis - new targets for cancer chemotherapy. Semin. Cancer Biol. 3:417-427.
8. Carson, D.A., and J.M. Ribeiro. 1993. Apoptosis and disease. Lancet. 341:1251-1254.
9. Fisher, D.E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:539-542.
10. Kerr, J.F.R., C.M. Winterford, and B.V. Harmon. 1994. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:2013-2026.
11. Thompson, C.B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science (Wash. DC). 267:1456-1462.
12. Mesner, P.W., I.I. Budihardjo, and S.H. Kaufmann. 1997. Chemotherapy-induced apoptosis. In Apoptosis: Pharmacologic Implications and Therapeutic Opportunities. S.H. Kaufmann, editor, Academic Press, San Francisco. In press.
13. Slagle, B.L., Y.-Z. Zhou, and J.S. Butel. 1991. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in the virus positive hepatocellular carcinoma. Cancer Res. 51:49-54.
14. Murakami, Y., K. Hayashi, S. Hirohashi, and T. Sekiya. 1991. Aberrations of the tumor suppresser p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:5520-5525.
15. Ozturk, M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 338:1356-1359.
16. Tanaka, S., Y. Toh, E. Adachi, T. Matsumata, R. Mori, and K. Sugimachi. 1993. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 53:2884-2887.
17. Lowe, S.W. 1995. Cancer therapy and p53. Curr. Opin. Oncol. 7:547-553.
18. Kaufmann, S.H. 1989. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 49:5870-5878.
19. Slichenmyer, W.J., W.G. Nelson, R.J. Slebos, and M.B. Kastan. 1993. Loss of p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168.
20. Uckun, F.M., C.F. Stewart, G. Reaman, L.M. Chelstrom, J. Jin, M. Chandan-Langlie, K.G. Waddick, J. White, and W.E. Evans. 1995. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood. 85:2817-2828.
21. Pommier, Y., F. Leteurtre, M.R. Fesen, A. Fujimori, R. Bertrand, and E. Solary. 1994. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:530-542.
22. Froelich-Ammon, S.J., and N. Osheroff. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanisms. J. Biol. Chem. 270:21429-21432.
23. Liu, L.F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-376.
24. Solary, E., R. Bertrand, and Y. Pommier. 1994. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemia HL-60 cells. Leukemia and Lymphoma. 15:21-32.
25. Planchon, S.M., S. Wurzberger, B. Frydman, D.T. Witiak, P. Hutson, D.R. Church, G. Wilding, and D.A. Boothman. 1995. β-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55:3706-3711.
26. Li, C.J., C. Wang, and A.B. Pardee. 1995. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res. 55:3712-3715.
27. Bruno, S., G. Del Bino, P. Lassota, W. Giaretti, and Z. Darzynkiewicz. 1992. Inhibitors of proteases prevent endonucleosis accompanying apoptotic death of HL-60 leukemic cells and normal thymocytes. Leukemia. 6:1113-1120.
28. Bruno, S., P. Lassota, W. Giaretti, and Z. Darzynkiewicz. 1992. Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to Go cells and is prevented by inhibitors of proteases. Oncol. Res. 3: 29-35.
29. Kaufmann, S.H., S. Desnoyers, Y. Ottaviano, N.E. Davidson, and G.G. Poirier. 1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976-3985.
30. Martin, S.J., and D.R. Green. 1995. Protease activation during apoptosis: death by a thousand cuts? Cell. 82:349-352.
31. Nicholson, D.W. 1996. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat. Biotech. 14:297-301.
32. Andrew, F., and G. Evan. 1996. License to kill. Cell. 85:781-784.
33. Kaufmann, S.H. 1996. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol. Med. Today. 2:18-23.
34. Puisieux, A., S. Lim, J. Groopman, and M. Ozturk. 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51:6185-6189.
35. Gores, G.J., A.L. Nieminen, B.E. Wray, B. Herman, and J.J. Lemaster. 1989. Intracellular pH during "chemical hypoxia" in cultured rat hepatocytes. Pretection by intracellular acidosis against onset of cell death. J. Clin. Invest. 83: 386-396.
36. Kaufmann, S.H., J.J. McLaughlin, M.B. Kastan, L.F. Liu, J.E. Karp, and P.J. Burke. 1991. Topoisomerase II levels during granulocyte maturation in vitro and in vivo. Cancer Res. 51:3534-3543.
37. Oberhammer, F.A., M. Pavelka, S. Sharma, R. Tiefenbacher, A.F. Purchio, W. Bursch, and R. Schulte-Hermann. 1992. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA. 89:5408-5412.
38. Patel, T., S.F. Bronk, and G.J. Gores. 1994. Increase of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94:2183-2192.
39. Kwo, P., T. Patel, S.F. Bronk, and G.J. Gores. 1995. Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am. J. Physiol. 268:G613-G621.
40. Que, F.G., G.J. Gores, and N.F. LaRusso. 1997. Development and initial application of an in vitro model of apoptosis in rodent cholangiocytes. Am. J. Physiol. In press.
41. Kostura, M.J., M.J. Tocci, G. Limjuco, J. Chin, P. Cameron, A.G. Hillman, N. A. Chartrain, and J. A. Schmidt. 1989. Identification of a monocyte specific pre-interleukin 1β convertase activity. Proc. Natl. Acad. Sci. USA. 86: 5227-5231.
42. Douglas, K.M., J.M. Ayala, L.A. Egger, S.M. Raju, T.T. Yamin, G.J.F. Ding, E.P. Gaffney, A.D. Howard, O.C. Palyha, A.M. Rolando, et al. 1993. Purification and characterization of active human interleukin-1β-converting enzyme from THP.1 monocytic cells. J. Biol. Chem. 268:18062-18069.
43. Martins, L.M, T. Kottke, P.W. Mesner, G.S. Basi, S. Sinha, N. Frigon, Jr., E. Tatar, J.S. Tung, K. Bryant, A. Takahashi, et al. 1997. Activation of multiple ICE-related proteases in HL-60 human leukemia cells during etoposide-induced apoptosis. J. Biol. Chem. In press.
44. Rosser, B.G., S.P. Powers, and G.J. Gores. 1993. Calpain activity increases in hepatocytes following addition of ATP: demonstration by a novel fluorescent approach. J. Biol. Chem. 268:23593-23600.
45. Koch, C.J., and A.R. Giandomenico. 1993. The alkaline elution technique for measuring DNA single strand breaks: increased reliability and sensitivity. Anal. Biochem. 220:58-65.
46. Chang, J.Y., L.A. Dethlefsen, L.R. Barley, B.S. Zhou, and Y.C. Cheng. 1992. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol. 43:2443-2452.
47. Boege, F., A. Anderson, S. Jensen, R. Zeidler, and H. Kreipe. 1995. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am. J. Pathol. 146:1302-1308.
48. Lamarre, D., B. Talbot, G. de Murcia, C. Laplante, Y. Leduc, A. Mazen, and G.G. Poirier. 1996. Structural and functional analysis of poly(ADP ribose) polymerase: an immunological study. Biochim. Biophys. Acta. 950:147-160.
49. xl function upstream of the CED-3-like apoptotic proteases. J. Biol. Chem. 271:4573-4576.
50. Kaufmann, S.H. 1989. Additional members of the rat liver lamin polypeptide family. Structural and immunological characterization. J. Biol. Chem. 264:13946-13955.
51. Cerretti, D.P., C.J. Kozlosky, B. Mosley, N. Nelson, K. Van Ness, T.A. Greenstreet, C.J. March, S.R. Kronheim, T. Druck, L.A. Cannizzaro, et al. 1992. Molecular cloning of the interleukin-1 beta converting enzyme. Science (Wash. DC). 256:97-100.
52. Munday, N.A., J.P. Vaillacourt, A. Ali, F.J. Casano, D.K. Miller, S.M. Molineaux, T.T. Yamin, V.L. Yu, and D.W. Nicholson. 1995. Molecular cloning and pro-apoptotic activity of ICErel II and ICErel III, members of the ICE/ CED-3 family of cysteine proteases. J. Biol. Chem. 270:15870-15876.
53. Wang, L., M. Miura, L. Bergeron, H. Zhu, and J. Yuan. 1994. Ich-1, an Ice/Ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell. 78:739-750.
54. Alnemri, T.F., G. Litwack, and E.S. Alnemri. 1994. CPP32, a novel human apoptotic protein with homology to caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem. 269:30761-30764.
55. Alnemri, T.F., G. Litwack, and E.S. Alnemri. 1995. Mch2, a new member of the apoptotic ced-3/Ice cysteine protease gene family. Cancer Res. 55: 2737-2742.
56. Alnemri, T.F., A. Takahashi, R. Armstrong, J. Krebs, L. Fritz, K.J. Tomaselli, L. Wang, Z. Yu, C.M. Croce, G. Salveson, et al. 1995. Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res. 55:6045-6052.
57. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidium thiocynate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
58. Adjei, A.A., M. Charron, E.K. Rowinsky, R.C. Donehower, J. Sebolt-Leopold, and S.H. Kaufmann. 1995. Pyrazoloacridine inhibits DNA topoisomerase (topo) I and II. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36:2079a. (Abstr.)
59. Beidler, D.R., and Y.C. Cheng. 1995. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47:907-914.
60. Kohn, K.W. 1996. DNA filter elution: a window on DNA damage in mammalian cells. BioEssays. 18:505-513.
61. Wozniak, A.J., and W.E. Ross. 1983. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-β-D- glucopyranoside) (etopostde) cytotoxicity. Cancer Res. 43:120-124.
62. Mattern, M.R., S.M. Mong, H.F. Bartus, C.K. Mirabelli, S.T. Crooke, and R.K. Johnson. 1987. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47:1793-1798.
63. Patel, T., G.J. Gores, and S.H. Kaufmann. 1996. The role of proteases during apoptosis. FASEB J. 10:587-597.
64. Takahashi, A., E.S. Alnemri, Y.A. Lazebnik, T.F. Alnemri, G. Litwack, R.D. Goldman, G.G. Poirier, S.H. Kaufmann, and W.C. Earnshaw. 1996. Cleavage of lamin A by Mch2α but not CPP32: multiple interleukin 1β-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc. Natl. Acad. Sci. USA. 93:8395-8400.
65. Schulte-Hermann, R., W. Bursch, B. Kraupp-Grasl, F. Oberhammer, and A. Wagner. 1992. Program cell death and its protective role with particular reference to apoptosis. Toxicol. Lett. 64:569-574.
66. Yuan, J., S. Shaham, S. Ledoux, J.M. Ellis, and J.R. Horvitz. 1993. The C. elegans cell death gene Ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell. 75:641-652.
67. Tewari, M., L.T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D.R. Beidler, G.G. Poirier, G.S. Salvesen, and V.M. Dixit. 1995. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 81 801-809.
68. Tang, C., M.C. Willingham, J.C. Reed, T. Miyashita, S. Ray, V. Ponnathpur, Y. Huang, M.E. Mahoney, G. Bullock, and K. Bhalla. 1994. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 8:1960-1969.
69. Rowinsky, E.K., D.A. Noe, L.B. Grochow, S.E. Sartorious, M.K. Bowling, T.L. Chen, B.G. Lubejko, S.H. Kaufmann, and R.C Donehower. 1995. Phase I and pharmacologie studies of pyrazoloacridine, a lovel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J. Clin. Oncol. 13: 1975-1984.
70. Zou, Y., I. Horikoshi, M. Ueno, X. Gu, and R. Patez-Soler. 1992. Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery. Int. J. Cancer. 51:232-237.